Business
Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence
About this update from Lantern Pharma Inc.
[{"type":"text","content":" DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, CEO and President, will present at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023. The fireside chat-style webcast will be available to all registered attendees. Details of the webcast can be found below:\n\n\n\nLytham Partners Spring 2023 Investor Conference, Thursday, May 18th at 9:00 a.m. ET.\nPresenter: Panna Sharma, CEO & President.\nWebcast Link: https://wsw.com/webcast/lytham8/ltrn/2066400\n\n\n\nLantern management will also be participating in one-on-one virtual investor meetings throughout the conference. To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at https://www.lythampartners.com/spring2023invreg/.\n\n\nAbout Lantern Pharma:\nLantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.\n\n\nOur lead development programs include two Phase 2 clinical programs and multiple upcoming Phase 1 clinical trials anticipated for 2023. We have also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 bil...